Predicting haloperidol treatment response in chronic schizophrenia

Daniel P. Van Kammen, Mary E. Kelley, Jeffrey K. Yao, Mark W. Gilbertson, John A. Gurklis, Takao Inosaka, Hidemitzu Saito, Jeffrey L. Peters, Mitsumoto Sato

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)


The study attempted to identify pretreatment characteristics of chronic schizophrenic patients that would predict remission in psychosis and amount of clinical improvement after treatment with haloperidol. Thirty-five acutely relapsed schizophrenic patients were entered into a blind 6-week treatment protocol. Pretreatment measures were assessed for prediction of both remission status (dichotomous) and for correlations with change in psychopathology (continuous). Later age of onset and higher plasma homovanillic acid values were significant predictors of remission status (model 1). However, higher cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylglycol, as well as indices of normal neurodevelopment, predicted larger changes in psychopathology. The results indicate that the definition of drug response determines the predictive variables. Dopaminergic activity seems to relate to the ability to reach remission, while noradrenergic activity relates to symptom intensity and reduction. In addition to catecholamine activity, neurodevelopmental changes determine response to haloperidol.

Original languageEnglish
Pages (from-to)47-58
Number of pages12
JournalPsychiatry Research
Issue number1
Publication statusPublished - 1996 Aug 30


  • 3-Methoxy-4-hydroxyphenylglycol
  • Computed tomography
  • Dopamine
  • Homovanillic acid
  • Norepinephrine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Predicting haloperidol treatment response in chronic schizophrenia'. Together they form a unique fingerprint.

Cite this